Zum Hauptinhalt springen
Nicht aus der Schweiz? Besuchen Sie lehmanns.de
Immunopotentiators in Modern Vaccines -

Immunopotentiators in Modern Vaccines

Buch | Hardcover
384 Seiten
2005
Academic Press Inc (Verlag)
9780120884032 (ISBN)
CHF 269,95 inkl. MwSt
zur Neuauflage
  • Titel erscheint in neuer Auflage
  • Artikel merken
Zu diesem Artikel existiert eine Nachauflage
Provides an insight and overview of immunopotentiators in vaccines. This book contains data on the critical mechanisms governing the activity of vaccine adjuvants and delivery systems. It also gives illustrated, informative figures that present the interactions between immunopotentiators and the host immune system.
Immunopotentiators in Modern Vaccines provides an in-depth insight and overview of a number of most promising immunopotentiators in modern vaccines. In contrast to existing books on the subject it provides recent data on the critical mechanisms governing the activity of vaccine adjuvants and delivery systems. Knowledge of immunological pathways and scenarios of the cells and molecules involved is described and depicted in comprehensive illustrations.

Dr. Virgil E.J.C. Schijns is special guest Professor in Cell Biology & Immunology group, Wageningen University, 6708 WD Wageningen, The Netherlands. Dr. Schijns received his PhD degree at Utrecht University in 1990. Recent professional appointments are Chief Scientific Officer at ERC in Belgium and The Netherlands, (2011 to present); Chief Technology Officer, Vice President at a small biotech spin-off from Utrecht University (2008 to 2011); Special Professor, Immune Intervention, Wageningen University and Research Center (2008 to present); Special Professor in Immunology and Virology at North Carolina State University (NCSU), Raleigh. Department of Population Health and Pathobiology (2002 to present) and Head of Department for Vaccine Technology and Immunology (VTI), AKZO NOBEL (1999 to 2008). Dr. Derek T. O’Hagan is a formulation scientist and vaccine adjuvant expert with extensive industry experience. He served as Global Head of Vaccine Chemistry and Formulation Research at Novartis Vaccines before its acquisition by GSK. With a background in pharmacy from the UK, he has worked in vaccine delivery research since 1993, including academic roles at the University of Nottingham. Dr. O’Hagan has led research on adjuvants such as MF59, now licensed in flu vaccines in over 40 countries. He has authored over 140 research publications, 60+ patents, and numerous book chapters. Recognized for innovation, he received the Royal Pharmaceutical Society’s Conference Science Medal and the Controlled Release Society’s Young Investigator Award. His work focuses on adjuvant development, nucleic acid vaccines, and needle-free delivery systems, making him a leading figure in vaccine formulation science.

Preface

List of contributors

Part I: Perspective on immunological mechanisms underlying adjuvant activity

Chapter 1: Unraveling “the immunologist’s dirty little secret”

Part II: Host-derived immunopotentiators

Chapter 2: Dendritic cells as targets and tools in vaccines

Chapter 3: Host-derived molecules as adjuvants

Part III: Natural and synthetic immunopotentiators

Chapter 4: Innate immune mechanisms and the identification of immune potentiators as vaccine adjuvants

Chapter 5: CpG oligodeoxynucleotides as vaccine adjuvants

Chapter 6: Toll-like receptor 4 agonists as vaccine adjuvants

Chapter 7: Immunomodulatory adjuvants from Quillaja saponaria

Part IV: Particulate immunopotentiators and delivery systems

Chapter 8: Microparticles as vaccine delivery systems

Chapter 9: MF59: a safe and potent adjuvant for human use

Chapter 10: Development and evaluation of AS04, a novel and improved adjuvant system containing MPL and aluminum salt

Chapter 11: Virosomes for vaccine delivery

Chapter 12: The ISCOMATRIXâ„¢ adjuvant

Chapter 13: Mineral adjuvants

Part V: Mucosal/nonparenteral adjuvants

Chapter 14: Mucosal adjuvants based on cholera toxin and E. coli heat-labile enterotoxin

Chapter 15: Transcutaneous immunization using the heat-labile enterotoxin of E. coli as an adjuvant

Part VI: Th-1/CTL adjuvants

Chapter 16: T cell adjuvants and novel strategies for their identification

Part VII: Adjuvants in noninfectious disease vaccines

Chapter 17: Vaccination to treat noninfectious diseases: surveying the opportunities

Part VIII: Clinical practice

Chapter 18: Clinical evaluation of adjuvants

Chapter 19: Regulatory considerations in the nonclinical safety assessment of adjuvanted preventive vaccines

Index

Erscheint lt. Verlag 19.12.2005
Verlagsort San Diego
Sprache englisch
Maße 189 x 246 mm
Gewicht 990 g
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
ISBN-13 9780120884032 / 9780120884032
Zustand Neuware
Informationen gemäß Produktsicherheitsverordnung (GPSR)
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich